BRIEF—Sanofi announces launch of Verorab in UK

French pharma major Sanofi today announced the UK launch of Verorab (Sanofi Inactivated Rabies Vaccine) an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups.

This launch is based on extensive clinical data from over 13,000 individuals.

Sanofi Inactivated Rabies Vaccine has been approved and widely used in more than 80 countries.

It is estimated that between 41 and 70 million individuals have received the vaccine since its first licensure in May 1985, in France.

Rebecca Catterick, UK and Ireland Sanofi Vaccines general manager said: “Rabies is a fatal, travel-related vaccine-preventable disease. The availability of Verorab in the UK provides an effective immunization option for those travelling to high-risk countries, as well as a treatment for post-rabies exposure.”

Rabies is nearly always fatal once symptoms appear but can be preventable with vaccination. Each year, an estimated 59,000 people worldwide die from rabies.